Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R21DA052864-01A1 | U.S. NIH Grant/Contract | View source | |
| 2K12DA000167-31 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand [11C] OMAR, in healthy individuals and individuals diagnosed with opioid use disorder. Research participants may complete screening, MRI, PET scan and follow up visits.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy Volunteers | Other | Healthy volunteers with no current or past major medical or psychiatric history |
|
| Opioid Use Disorder | Other | Patients diagnosed with opioid use disorder |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| [11C]OMAR | Drug | For each [11C]OMAR PET scan, up to 20 mCi of [11C]OMAR will be administered. |
|
| Measure | Description | Time Frame |
|---|---|---|
| CB1R Availability | To compare cortical CB1R availability in individuals diagnosed with opioid use disorder on chronic methadone maintenance vs. matched healthy controls. | One time within 4 weeks of screening |
| Measure | Description | Time Frame |
|---|---|---|
| Serum Endocannabinoid Levels | To explore group differences in serum endocannabinoid levels in individuals diagnosed with opioid use disorder on chronic methadone maintenance vs. matched healthy controls. | One time within 4 weeks of screening |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anahita Bassir Nia, MD | Contact | 203-974-7540 | anahita.bassirnia@yale.edu | |
| Angelina Contreras | Contact | 203-626-1105 | angelina.contreras@yale.edu |
| Name | Affiliation | Role |
|---|---|---|
| Anahita Bassir Nia, MD | Yale University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Connecticut Mental Health Center, Clinical Neuroscience Research Unit | Recruiting | New Haven | Connecticut | 06519 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009293 | Opioid-Related Disorders |
| ID | Term |
|---|---|
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C515663 | 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided